SH3BP2 and gastrointestinal stromal tumor: As shown in Figure 1 and Supplementary Material S1, silencing of SH3BP2 reduces MITF, as previously reported, and ETV1 protein levels in imatinib-sensitive and imatinib-resistant GIST cell lines.